close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeOnc Technologies Holdings, Inc. - Common Stock (NQ:NTHI)

11.67 -0.31 (-2.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NeOnc Technologies Holdings, Inc. - Common Stock

< Previous 1 2 Next >
Meet the Companies - New to The Street's Accredited Investor Event Returns October 21-22 at Hudson Yards, NYC
Via ACCESS Newswire
NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
New to The Street to Broadcast Tonight on Fox Business 10:30 PM PST Featuring NeOnc Technologies, FLOKI, XION, Sharps Technology, and Aeries Technology
Via ACCESS Newswire
NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, to Its Scientific Advisory Board
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
New to The Street to Broadcast Saturday, September 27th Featuring NeOnc Pharma $NTHI and Other Innovative Companies
Via ACCESS Newswire
NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on “Health Uncensored with Dr. Drew” on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ET/PT
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
New to The Street to Broadcast Episode 686 Tonight on Bloomberg Television at 6:30 PM EST
Via ACCESS Newswire
NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
New to The Street's Esteemed Client NeOnc Technologies Finalizes $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation
Via ACCESS Newswire
NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
New to The Street Signs NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) to 12-Part National Broadcast Series Including T.V. Network Features, Earned Media, Commercials, and Iconic Outdoor Billboards
Via ACCESS Newswire
NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar Investment
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Conference
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Executes Sub-License Agreement, Marking Key Milestone Toward Closing $50 Million Strategic Partnership with Quazar Investment
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar Investment
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Holdings, Inc. Joins Russell Microcap® Index
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today